EXACT Sciences Corporation (EXAS) Shares are Down -7.12%

EXACT Sciences Corporation (EXAS) has risen sharply, recording gains of 10.41% in the past 4 weeks. However, the stock has corrected -7.12% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 10.65% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 2.25% and the fifty day Moving Average is 25.28%. Exact Sciences Corporation is up 195.23% in the last three month period. Year-to-Date the stock performance stands at 107.91%.

EXACT Sciences Corporation (EXAS) : 9 investment research analysts covering EXACT Sciences Corporation (EXAS) have an average price target of $15.78 for the near short term. The highest target price given by the Brokerage Firm to the stock is $26 and the lowest target is $8 for the short term. Analysts expect the variance to be within $5.91 of the average price.


EXACT Sciences Corporation (NASDAQ:EXAS): stock turned positive on Friday. Though the stock opened at $18.77, the bulls momentum made the stock top out at $19.42 level for the day. The stock recorded a low of $18.72 and closed the trading day at $19.19, in the green by 0.73%. The total traded volume for the day was 1,931,293. The stock had closed at $19.05 in the previous days trading.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.